血浆游离DNA数字化二代测序在肿瘤组织不足的晚期肺腺癌患者中的临床效用
这项多机构前瞻性队列研究纳入12家西班牙机构93例组织不足以进行EGFR、ALK或ROS1分型的晚期肺腺癌患者,采用73基因面板检测ctDNA。89%可检出ctDNA,57%存在可操作变异(14%为1-2A级),13%据此接受基因型匹配治疗,中位周转13天。
要点
- 93例组织不足的晚期肺腺癌患者中,89%可检出ctDNA,57%存在潜在可操作变异。
- 14%患者检出1-2A级变异(FDA批准及指南标准生物标志物),13%接受基因型匹配治疗。
- 合并其他致病变异者中位总生存显著缩短(多因素HR=5.35,P=0.01)。
核心结论
- 对于组织样本不足以进行组织测序的肺癌患者,ctDNA数字化二代测序可检出可操作变异,这些变异常与其他潜在临床相关基因组变异共存,从而允许及时启动基因型匹配治疗。
研究设计与样本
- 多机构前瞻性队列研究,纳入12家西班牙机构中临床未筛选的晚期肺腺癌患者,组织不足以进行EGFR、ALK或ROS1分型(n=93)。
- ctDNA二代测序由Guardant Health(Guardant360,Redwood City,CA)完成,采用基于杂交捕获的73基因面板。
- 变异若属于OncoKB精准肿瘤学知识数据库,则视为可操作,并根据药物反应的临床或临床前证据分为四个可操作性等级。
主要发现
- 93例患者中83例(89%)可检出ctDNA水平。
- 53例(57%)检出潜在可操作的1-4级基因组变异,其中13例(14%)为1-2A级变异(FDA批准及根据肺癌指南的标准治疗生物标志物)。
- 各基因组变异在ctDNA中的频率与未筛选肺腺癌中观察到的频率一致。
- 多数患者(62%),尤其是携带可操作变异的患者(87%),ctDNA中存在一个以上致病性变异。
- 基因组结果的中位周转时间为13天。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 30% of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield insufficient tissue for successful molecular subtyping. We have analyzed the clinical utility of next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA) in patients with inadequate tumor samples for tissue genotyping. PATIENTS AND METHODS: We conducted the study in a multi-institutional prospective cohort of clinically unselected patients with advanced-stage lung adenocarcinomas with insufficient tissue for EGFR, ALK or ROS1 genotyping across 12 Spanish institutions (n = 93). ctDNA NGS was carried out by Guardant Health (Guardant360, Redwood City, CA), using a hybrid-capture-based 73-gene panel. Variants were deemed actionable if they were part of the OncoKB precision oncology knowledge database and classified in four levels of actionability based on their clinical or preclinical evidence for drug response. RESULTS: Eighty-three out of 93 patients (89%) had detectable levels of ctDNA. Potentially actionable level 1-4 genomic alterations were detected in 53 cases (57%), of which 13 (14%) had level 1-2A alterations (Food and Drug Administration-approved and standard-care biomarkers according to lung cancer guidelines). Frequencies of each genomic alteration in ctDNA were consistent with those observed in unselected pulmonary adenocarcinomas. The majority of the patients (62%), particularly those with actionable alterations (87%), had more than one pathogenic variant in ctDNA. The median turnaround time to genomic results was 13 days. Twelve patients (13%) received genotype-matched therapies based on ctDNA results, deriving the expected clinical benefit. Patients with co-occurring pathogenic alterations had a significantly shorter median overall survival as compared with patients without co-occurring pathogenic alteration (multivariate hazard ratio = 5.35, P = 0.01). CONCLUSION: Digital NGS of ctDNA in lung cancers with insufficient tumor samples for tissue sequencing detects actionable variants that frequently co-occur with other potentially clinically relevant genomic alterations, allowing timely initiation of genotype-matched therapies.
引用
- Zugazagoitia J, Ramos I, Trigo JM, et al. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Ann Oncol. 2019. PMID: 30535340. doi:10.1093/annonc/mdy512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。